JP2024014894A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024014894A5 JP2024014894A5 JP2023189115A JP2023189115A JP2024014894A5 JP 2024014894 A5 JP2024014894 A5 JP 2024014894A5 JP 2023189115 A JP2023189115 A JP 2023189115A JP 2023189115 A JP2023189115 A JP 2023189115A JP 2024014894 A5 JP2024014894 A5 JP 2024014894A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament
- disorder
- composition according
- vitamin
- prevention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 9
- 230000002265 prevention Effects 0.000 claims 5
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 4
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 claims 3
- 229940093265 berberine Drugs 0.000 claims 3
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 claims 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- 208000020446 Cardiac disease Diseases 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 108010028554 LDL Cholesterol Proteins 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims 2
- 125000004494 ethyl ester group Chemical group 0.000 claims 2
- 208000010706 fatty liver disease Diseases 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 229940057917 medium chain triglycerides Drugs 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010070901 Diabetic dyslipidaemia Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 208000002231 Muscle Neoplasms Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims 1
- 229930003779 Vitamin B12 Natural products 0.000 claims 1
- 229930003268 Vitamin C Natural products 0.000 claims 1
- 229930003316 Vitamin D Natural products 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 1
- 229960002873 benfotiamine Drugs 0.000 claims 1
- BTNNPSLJPBRMLZ-LGMDPLHJSA-N benfotiamine Chemical compound C=1C=CC=CC=1C(=O)SC(/CCOP(O)(O)=O)=C(/C)N(C=O)CC1=CN=C(C)N=C1N BTNNPSLJPBRMLZ-LGMDPLHJSA-N 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 229940046374 chromium picolinate Drugs 0.000 claims 1
- GJYSUGXFENSLOO-UHFFFAOYSA-N chromium;pyridine-2-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1 GJYSUGXFENSLOO-UHFFFAOYSA-N 0.000 claims 1
- 150000001860 citric acid derivatives Chemical class 0.000 claims 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 230000002641 glycemic effect Effects 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000001000 lipidemic effect Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 201000002077 muscle cancer Diseases 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000001076 sarcopenia Diseases 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 229910052720 vanadium Inorganic materials 0.000 claims 1
- 229940045605 vanadium Drugs 0.000 claims 1
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 claims 1
- 235000019155 vitamin A Nutrition 0.000 claims 1
- 239000011719 vitamin A Substances 0.000 claims 1
- 235000019163 vitamin B12 Nutrition 0.000 claims 1
- 239000011715 vitamin B12 Substances 0.000 claims 1
- 235000019154 vitamin C Nutrition 0.000 claims 1
- 239000011718 vitamin C Substances 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Substances 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 229940045997 vitamin a Drugs 0.000 claims 1
- 229940046008 vitamin d Drugs 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562254739P | 2015-11-13 | 2015-11-13 | |
| CN201610303976.5 | 2016-05-10 | ||
| CN201610303976.5A CN106692973A (zh) | 2015-11-13 | 2016-05-10 | 一种组合物及其用途、药物制剂 |
| JP2018559306A JP2019518738A (ja) | 2015-11-13 | 2016-11-10 | 組成物、ならびにその適用および薬学的調製の方法 |
| PCT/CN2016/105294 WO2017193563A1 (zh) | 2015-11-13 | 2016-11-10 | 一种组合物及其用途、药物制剂 |
| JP2021180724A JP7448511B2 (ja) | 2015-11-13 | 2021-11-05 | 組成物、ならびにその適用および薬学的調製の方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021180724A Division JP7448511B2 (ja) | 2015-11-13 | 2021-11-05 | 組成物、ならびにその適用および薬学的調製の方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024014894A JP2024014894A (ja) | 2024-02-01 |
| JP2024014894A5 true JP2024014894A5 (enExample) | 2024-04-23 |
| JP7668859B2 JP7668859B2 (ja) | 2025-04-25 |
Family
ID=58939703
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559306A Pending JP2019518738A (ja) | 2015-11-13 | 2016-11-10 | 組成物、ならびにその適用および薬学的調製の方法 |
| JP2021180724A Active JP7448511B2 (ja) | 2015-11-13 | 2021-11-05 | 組成物、ならびにその適用および薬学的調製の方法 |
| JP2023189115A Active JP7668859B2 (ja) | 2015-11-13 | 2023-11-06 | 組成物、ならびにその適用および薬学的調製の方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559306A Pending JP2019518738A (ja) | 2015-11-13 | 2016-11-10 | 組成物、ならびにその適用および薬学的調製の方法 |
| JP2021180724A Active JP7448511B2 (ja) | 2015-11-13 | 2021-11-05 | 組成物、ならびにその適用および薬学的調製の方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11883539B2 (enExample) |
| JP (3) | JP2019518738A (enExample) |
| KR (1) | KR102892545B1 (enExample) |
| CN (2) | CN106692973A (enExample) |
| IL (2) | IL300237A (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108159037A (zh) * | 2017-12-29 | 2018-06-15 | 广东海洋大学 | 一种用于提高神经保护功能的不饱和脂肪酸组合物及其应用 |
| CN108042522A (zh) * | 2017-12-29 | 2018-05-18 | 广东海洋大学 | 一种用于提高抗炎症功能的不饱和脂肪酸组合物及其应用 |
| WO2024245370A1 (zh) * | 2023-05-31 | 2024-12-05 | 上海复宏汉霖生物技术股份有限公司 | 一种组合产品、盐及其用途 |
| WO2026006683A1 (en) * | 2024-06-28 | 2026-01-02 | Wisteria Therapeutics, Inc. | Omega-7 fatty acid berberine salt and methods of uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1983989T3 (da) * | 2006-02-09 | 2013-10-14 | Ca Nat Research Council | Kombinationer af botaniske ekstrakter til fremme af kardiovaskulær sundhed |
| US20080306154A1 (en) * | 2006-11-03 | 2008-12-11 | My Svensson | Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids |
| WO2009028457A1 (ja) * | 2007-08-29 | 2009-03-05 | Shinshu University | 非アルコール性脂肪肝炎治療薬 |
| WO2010104595A1 (en) * | 2009-03-11 | 2010-09-16 | Xintria Pharmaceutical Corporation, Inc. | Methods and compositions for the treatment of metabolic and cardiovascular disorders |
| ES2530049T3 (es) * | 2009-05-18 | 2015-02-26 | Sigmoid Pharma Limited | Composición que comprende gotas de aceite |
| CN101879162A (zh) * | 2010-02-23 | 2010-11-10 | 江苏格林生物科技有限公司 | 一种α-亚麻酸乙酯配伍小檗碱的减肥物 |
| US9119826B2 (en) * | 2011-02-16 | 2015-09-01 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels |
| CA2827561A1 (en) * | 2011-02-16 | 2012-08-23 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid diagniostic assay for the dietary management of patients with cardiovascular disease (cvd) |
| CN102580087B (zh) * | 2012-03-08 | 2013-08-21 | 董萍 | 一种可用于人体局部减肥和美体的原位脂肪细胞系复合抑制剂及其制备方法 |
| IN2014DN08449A (enExample) * | 2012-03-30 | 2015-05-08 | Sancilio & Company Inc | |
| US8652518B2 (en) * | 2012-04-15 | 2014-02-18 | Jahahreeh Finley | Compositions and methods for the prevention and treatment of diseases or conditions associated with oxidative stress, inflammation, and metabolic dysregulation |
| EP2968246A4 (en) * | 2013-03-13 | 2016-08-03 | Matinas Biopharma Inc | OMEGA-3-PENTAIC ACID COMPOSITIONS AND METHODS OF USE |
| US20140322314A1 (en) * | 2013-04-29 | 2014-10-30 | Matinas Biopharma, Inc. | Omega-3 Fatty Acid Formulations for Use as Pharmaceutical Treatment |
| WO2015034984A1 (en) * | 2013-09-05 | 2015-03-12 | Emory University | Nutritional formulas comprising medium chain fatty acids or esters thereof and methods related thereto |
| BR112017001623B1 (pt) * | 2014-07-29 | 2022-11-29 | Shenzhen Hightide Biopharmaceutical, Ltd | Sal de adição ácido-base em uma forma substancialmente pura, composição farmacêutica compreendendo uma quantidade do referido sal e seus usos |
| MA40846A (fr) * | 2014-10-10 | 2017-09-05 | Sancilio & Company Inc | Compositions d'acides gras et d'esters d'acides gras auto-micellisantes, ainsi que leur utilisation dans le traitement d'états pathologiques |
| US9446100B2 (en) * | 2015-02-13 | 2016-09-20 | Eastern Vision Limited | Dietary supplements and formulations |
-
2016
- 2016-05-10 CN CN201610303976.5A patent/CN106692973A/zh active Pending
- 2016-05-10 CN CN202310452983.1A patent/CN116492339A/zh active Pending
- 2016-11-10 KR KR1020187034961A patent/KR102892545B1/ko active Active
- 2016-11-10 JP JP2018559306A patent/JP2019518738A/ja active Pending
- 2016-11-10 IL IL300237A patent/IL300237A/en unknown
-
2018
- 2018-11-11 IL IL262929A patent/IL262929B2/en unknown
-
2021
- 2021-11-05 JP JP2021180724A patent/JP7448511B2/ja active Active
-
2022
- 2022-05-15 US US17/744,685 patent/US11883539B2/en active Active
-
2023
- 2023-11-06 JP JP2023189115A patent/JP7668859B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024014894A5 (enExample) | ||
| JP5922868B2 (ja) | 脂質異常症の改善または治療薬 | |
| Song et al. | Combined effect of n-3 fatty acids and phytosterol esters on alleviating hepatic steatosis in non-alcoholic fatty liver disease subjects: A double-blind placebo-controlled clinical trial | |
| HRP20210686T1 (hr) | Pripravci i postupci za liječenje moždanog udara kod subjekta na istodobnoj terapiji statinom | |
| JP6321074B2 (ja) | ドナリエラ属（Ｄｕｎａｌｉｅｌｌａ）の粉末の治療的使用 | |
| JP2009515815A (ja) | アゼチジノン系コレステロール吸収阻害剤及びオメガ−３脂肪酸を用いた治療、並びにそれらの併用品 | |
| JP2008524120A (ja) | オメガ−３脂肪酸類及びｐｐａｒアゴニスト及び／又はアンタゴニスト並びにその併用製品を用いた治療 | |
| JP2009256392A5 (enExample) | ||
| KR20240011872A (ko) | 15-hepe를 포함하는 조성물 및 그의 사용 방법 | |
| EP3569250B1 (en) | Pemafibrate in combination with a sglt2 inhibitor for the prophylactic or therapeutic treatment of liver diseases nonalcoholic fatty liver disease | |
| JP7668859B2 (ja) | 組成物、ならびにその適用および薬学的調製の方法 | |
| JP2009544701A (ja) | オメガ３脂肪酸を含む組成物、ならびに末梢動脈障害および間欠性跛行を処置するためのそれらの使用 | |
| CN105232525A (zh) | 一种降血脂药物组合物及其应用 | |
| AU2016223109B2 (en) | Millicapsule formulations comprising polyunsaturated free fatty acids | |
| Charbonnel | PPAR-α and PPAR-γ agonists for type 2 diabetes | |
| CN115531406A (zh) | 芒柄花苷在制备预防或治疗脂肪肝药物中的应用 | |
| CN102824636A (zh) | 一种含他汀类药物和多不饱和脂肪酸的药物组合物及其用途 | |
| JP2010229099A (ja) | 脂質異常症の改善または治療薬 | |
| Tahir et al. | Biological activities of evening primrose oil | |
| JP2018197273A (ja) | 脂質異常症治療剤 | |
| JPWO2013005834A1 (ja) | 高純度ｅｐａを含有する抗肥満剤 | |
| CN117679497A (zh) | 脂蛋白脂肪酶在制备治疗非酒精性脂肪肝产品中的应用 | |
| WO2021138742A1 (en) | Composition that promote pro-resolving mediators | |
| Holub | Treating hypertriglyceridemia | |
| CN115707467A (zh) | 包含小檗碱和二甲双胍的药物组合物及其治疗或预防动脉粥样硬化的用途 |